Latency to selective serotonin reuptake inhibitor vs benzodiazepine treatment in patients with panic disorder: a naturalistic study
- 5 November 2021
- journal article
- research article
- Published by Cambridge University Press (CUP) in CNS Spectrums
- Vol. 28 (1), 46-52
- https://doi.org/10.1017/s1092852921000869
Abstract
Background Panic disorder (PD) is a prevalent and impairing anxiety disorder with previous reports suggesting that the longer the condition remains untreated, the greater the likelihood of nonresponse. However, patients with PD may wait for years before receiving a guideline-recommended pharmacological treatment. The widespread prescription of benzodiazepines (BDZ) for managing anxiety symptoms and disorders might delay the administration of pharmacotherapy according to guidelines (eg, selective serotonin reuptake inhibitors, SSRIs). The present study aimed to determine the mean duration of untreated illness (DUI) in a sample of PD patients, to quantify and compare DUI-SSRI to DUI-BDZ, and to compare findings with those from previous investigations. Methods Three hundred and fourteen patients with a Diagnostic and Statistical Manual of Mental Disorders, fifth edition diagnosis of PD were recruited from an Italian outpatient psychotherapy unit, and epidemiological and clinical variables were retrieved from medical records. Descriptive statistical analyses were undertaken for sociodemographic and clinical variables, Wilcoxon matched-pair signed rank test was applied to compare the distribution of DUI-SSRI vs DUI-BDZ, and Welch’s t test was performed to compare findings with those from previous studies. Results The mean DUI-SSRI of the total sample was 64.25 ± 112.74 months, while the mean DUI-BDZ was significantly shorter (35.09 ± 78.62 months; P < 0.0001). A significantly longer DUI-SSRI, compared to findings from previous studies, was also observed. Conclusions The present results confirm a substantial delay in implementing adequate pharmacological treatments in patients with PD, and highlight the discrepancy between recommendations from international treatment guidelines and common clinical practice in relation to BDZ prescription.Keywords
This publication has 52 references indexed in Scilit:
- The influence of age at onset and duration of illness on long-term outcome in patients with obsessive-compulsive disorder: A report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS)European Neuropsychopharmacology, 2013
- The effects of comorbid personality disorders on cognitive behavioral treatment for panic disorderJournal of Psychiatric Research, 2011
- New treatment options for panic disorder: clinical trials from 2000 to 2010Expert Opinion on Pharmacotherapy, 2011
- Age at onset and latency to treatment (duration of untreated illness) in patients with mood and anxiety disorders: a naturalistic studyInternational Clinical Psychopharmacology, 2010
- Duration of Untreated Illness as a Predictor of Treatment Response and Remission in Obsessive–Compulsive DisorderThe World Journal of Biological Psychiatry, 2009
- Do Comorbid Personality Disorders Moderate Panic-Focused Psychotherapy?Published by Physicians Postgraduate Press, Inc ,2007
- Alcohol Use Disorders and Panic DisorderBritish Journal of Psychology, 2007
- The Epidemiology of Panic Attacks, Panic Disorder, and Agoraphobia in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2006
- Prolonged duration of untreated psychosis in nonaffective first-episode psychotic disorders compared to other psychosesInternational Journal of Psychiatry in Clinical Practice, 2006
- Are Benzodiazepines Still the Medication of Choice for Patients With Panic Disorder With or Without Agoraphobia?American Journal of Psychiatry, 2003